An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.

Alessandra Mosca, Ugo De Giorgi, Camillo Porta, Giuseppe Procopio, Umberto Basso, Giacomo Cartenì, Matteo Bersanelli, Emanuele Naglieri, L. Galli, Orazio Caffo, Giuseppe Fornarini, F Boccardo, C. Porta

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials. Methods: Retrospective analysis (the PAMERIT study) of first-line pazopanib in real-world metastatic renal cell cancer patients among 39 Centers in Italy. Outcomes were progression-free survival, overall survival, objective response rate and treatment-related adverse events. Kaplan-Meier curves, log-rank test and multivariable Cox's models were used and adjusted for age, histology, previous renal surgery, International Metastatic RCC Database Consortium score and pazopanib initial dose. Results: Among 474 patients, 87.3% had clear cell metastatic renal cell cancer histology. Most of them (84.6%) had upfront renal surgery. Median progression-free survival and overall survival were 15.8 and 34.4 months, respectively, significantly correlating with International Metastatic RCC Database Consortium's good prognosis (P < 0.001), ECOG PS 0 (P < 0.001), age (
Original languageEnglish
Pages (from-to)484-491
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume51
Issue number3
DOIs
Publication statusPublished - Mar 3 2021

Fingerprint

Dive into the research topics of 'An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.'. Together they form a unique fingerprint.

Cite this